top of page


Harvey L. Katzeff, M.D.

Chief Medical Officer (CMO)

Dr. Katzeff is an US physician with board certification in both internal medicine and endocrinology & metabolism. He is well established and recognized in the medical community of Type 1 and Type 2 diabetes given his close to 40 years of experiences covering career tracks in industry, academia and clinical practice.


Harvey was the executive director of Scientific and Medical Affairs at Merck Research Labs and the Chair of its Investigator Initiated Trial program as well as heavily involvement in the medical & preclinical strategy of its diabetes franchise and Januvia, the first DPP-4 inhibitor approved for treating Type 2 Diabetes. He later took on the responsibilities of senior medical director within various CROs including IQVIA Biotech, PRA Health and Covance, contributing his knowledge and monitoring for numerous clinical studies from phase 1 to 3.


Prior to his industry career, Harvey has been an Associate Professor of Medicine with Cornell Medical College and Albert Einstein College of Medicine, and the Chief, Division of Endocrinology, at Northwell  & Long Island Jewish Medical Centers.  He was the recipient of NIH postdoctoral traineeship and New Investigator awards as well as several RO1 grants in the fields of obesity and Diabetes Mellitus. He was an original co-investigator of the landmark DCCT trial and a clinical investigator for numerous diabetes and metabolic studies. 

bottom of page